{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:53:40Z","timestamp":1793753620840,"version":"4.6.1"},"reference-count":133,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002806","name":"Carl Zeiss Meditec AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.survophthal.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:34:01Z","timestamp":1758090841000},"page":"289-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7176-6631","authenticated-orcid":false,"given":"Keean","family":"Nanji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Hatamnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Grad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"El-Sayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Gemae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Guymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih Chung","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunir J.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-4146","authenticated-orcid":false,"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.survophthal.2025.09.009_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ophtha.2009.10.002","article-title":"Factors associated with improvement and worsening of visual acuity 2 years after focal\/grid photocoagulation for diabetic macular edema","volume":"117","author":"Aiello","year":"2010","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1016\/j.survophthal.2025.09.009_bib2","first-page":"1747","article-title":"Initial choroidal thickness and response to treatment in diabetic macular edema","volume":"55","author":"Bagheri","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.009_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/IAE.0000000000002253","article-title":"Aflibercept for persistent diabetic macular edema: Forty-eight-week outcomes","volume":"39","author":"Bahrami","year":"2019","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.009_bib4","first-page":"2702","article-title":"Relationship between retinal structural abnormalities and visual outcomes in the phase 2 boulevard trial for diabetic macular edema","volume":"64","author":"Balasubramanian","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.009_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib6","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1167\/iovs.16-20305","article-title":"The systemic blood pressure and oxygen saturation in retinal arterioles predict the effect of intravitreal Anti-VEGF treatment on diabetic maculopathy","volume":"57","author":"Bek","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.09.009_bib7","doi-asserted-by":"crossref","unstructured":"Bezzina A.D., Carbonaro F. Factors predicting treatment response in anti-vascular endothelial growth factor na\u00efve diabetic macular edema patients treated with intravitreal bevacizumab. https:\/\/home.liebertpub.com\/jop. 2019;35(10):551-557. doi:10.1089\/JOP.2018.0112.","DOI":"10.1089\/jop.2018.0112"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib8","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1111\/aos.13935","article-title":"Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers","volume":"97","author":"Bonfiglio","year":"2019","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.09.009_bib9","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.ophtha.2015.08.006","article-title":"Outcomes with as-needed ranibizumab after initial monthly therapy: Long-term outcomes of the phase III RIDE and RISE trials","volume":"122","author":"Boyer","year":"2015","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.009_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/bjo.2006.105783","article-title":"Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study","volume":"91","author":"Brasil","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.6786","article-title":"Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with Anti-Vascular endothelial growth factor therapy: an exploratory analysis of the protocol t randomized clinical trial","volume":"137","author":"Bressler","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.09.009_bib12","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","article-title":"Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab","volume":"130","author":"Bressler","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.009_bib13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/IAE.0b013e318194995d","article-title":"Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables","volume":"29","author":"Browning","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2025.09.009_bib14","doi-asserted-by":"crossref","unstructured":"Campos A., Campos E.J., Do Carmo A., et al. Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema. doi:10.1007\/s00417-018-4072-z.","DOI":"10.1007\/s00417-018-4072-z"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.009_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00592-019-01389-4","article-title":"Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema","volume":"57","author":"Cavalleri","year":"2020","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib16","doi-asserted-by":"crossref","unstructured":"Chang Y.C.;, Huang Y.T.;, Hsu A.Y. et al. Optical coherence tomography biomarkers in predicting treatment outcomes of diabetic macular edema after ranibizumab injections. Published online 2023. doi:10.3390\/medicina59030629.","DOI":"10.3390\/medicina59030629"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.009_bib17","article-title":"Optical coherence tomography biomarkers in predicting treatment outcomes of diabetic macular edema after ranibizumab injections","volume":"59","author":"Chang","year":"2023","journal-title":"Med (B Aires)"},{"key":"10.1016\/j.survophthal.2025.09.009_bib18","unstructured":"Chapter 12: Synthesizing and presenting findings using other methods | Cochrane Training. Accessed May 17, 2024. \u3008https:\/\/training.cochrane.org\/handbook\/current\/chapter-12#_Ref524788567\u3009."},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.009_bib19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/08820538.2022.2069470","article-title":"The impact of laboratory findings and optical coherence tomography biomarkers on response to intravitreal Anti-VEGF treatment in patients with diabetic macular edema","volume":"37","author":"Chatziralli","year":"2022","journal-title":"Semin Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/15569527.2020.1802741","article-title":"Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors","volume":"39","author":"Chatzirallis","year":"2020","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib21","doi-asserted-by":"crossref","unstructured":"Chen Y.P., Wu A.L., Chuang C.C., Chen S.N. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. doi:10.1038\/s41598-019-47241-1.","DOI":"10.1038\/s41598-019-47241-1"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.009_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/IAE.0000000000003271","article-title":"Foveal m\u00fcller cell cone as a prognostic optical coherence tomography biomarker for initial response to antivascular endothelial growth factor treatment in cystoid diabetic macular edema","volume":"42","author":"Choi","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2025.09.009_bib23","doi-asserted-by":"crossref","unstructured":"Chou H.D., Wu C.H., Chiang W.Y., et al. Optical coherence tomography and imaging biomarkers as outcome predictors in diabetic macular edema treated with dexamethasone implant. Published online 123AD. doi:10.1038\/s41598-022-07604-7.","DOI":"10.1038\/s41598-022-07604-7"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.009_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/humupd\/dmh058","article-title":"Balancing the strengths of systematic and narrative reviews","volume":"11","author":"Collins","year":"2005","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.survophthal.2025.09.009_bib25","unstructured":"CRAN: Package XNomial. Accessed June 9, 2024. \u3008https:\/\/cran.r-project.org\/web\/packages\/XNomial\/index.html\u3009."},{"key":"10.1016\/j.survophthal.2025.09.009_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3033219","article-title":"Choroidal vascularity index as a biomarker for visual response to antivascular endothelial growth factor treatment in diabetic macular edema","volume":"2021","author":"Dou","year":"2021","journal-title":"J Diabetes Res"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.009_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000002110","article-title":"Association between early anatomic response to Anti-Vascular endothelial growth factor therapy and Long-Term outcome in diabetic macular edema: an independent analysis of protocol I study data","volume":"39","author":"Dugel","year":"2019","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.009_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5301\/ejo.5000655","article-title":"Evaluation of inner and outer retinal thickness in patients receiving intravitreal ranibizumab injections for diabetic macular edema","volume":"26","author":"Dursun","year":"2015","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.009_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1120672118782102","article-title":"Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study)","volume":"29","author":"Ehrlich","year":"2019","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/jop.2018.0082","article-title":"Outcome and predictors for 2-Year visual acuity in eyes with diabetic macular edema treated with ranibizumab","volume":"35","author":"Eski Yucel","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.009_bib31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3928\/15428877-20071101-06","article-title":"Can optical coherence tomography predict the outcome of laser photocoagulation for diabetic macular edema?","volume":"38","author":"Estabrook","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.009_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000489046","article-title":"Ranibizumab for the treatment of diabetic macular oedema in the Real-World clinical setting in Portugal: a multicentre study","volume":"241","author":"Farinha","year":"2019","journal-title":"Ophthalmologica"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/IAE.0000000000001626","article-title":"Predictive value of optical coherence tomographic features in the bevacizumab and ranibizumab in patients with diabetic macular edema (BRDME) study","volume":"38","author":"Fickweiler","year":"2018","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.009_bib34","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy preferred practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.009_bib35","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00417-019-04446-4","article-title":"Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex\u00ae) outcomes in diabetic macular edema: a multicenter study","volume":"257","author":"Fonollosa","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","article-title":"GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks","volume":"121","author":"Foroutan","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.009_bib37","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","article-title":"Treat-And-Extend regimens with Anti-Vegf agents in retinal diseases","volume":"35","author":"Freund","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2025.09.009_bib38","doi-asserted-by":"crossref","unstructured":"Gabrielle P.H., Massin P., Arnould L., et al. Development of a 1-year risk-prediction nomogram for good functional response with anti-VEGF agents in naive diabetic macular oedema. doi:10.1111\/aos.14428.","DOI":"10.1111\/aos.14428"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.009_bib39","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1111\/aos.14428","article-title":"Development of a 1-year risk-prediction nomogram for good functional response with anti-VEGF agents in naive diabetic macular oedema","volume":"98","author":"Gabrielle","year":"2020","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.009_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bjophthalmol-2017-310483","article-title":"Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema","volume":"102","author":"Gerendas","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000514721","volume":"64","author":"Giannakaki-Zimmermann","year":"2021","journal-title":"Ophthalmic Res"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.009_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/eci.12931","article-title":"Time to challenge the spurious hierarchy of systematic over narrative reviews?","volume":"48","author":"Greenhalgh","year":"2018","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"10.1016\/j.survophthal.2025.09.009_bib43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/tvst.9.12.8","article-title":"A novel approach to quantitative evaluation of outer retinal lesions via a new parameter \u201cIntegral\u201d in spectral domain optical coherence tomography","volume":"9","author":"Gu","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib44","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032815","article-title":"Optical coherence tomography classifications of diabetic macular edema and response to aflibercept: One-year follow-up outcomes in a Chinese population","volume":"102","author":"Gu","year":"2023","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.009_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40942-023-00453-0","article-title":"Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice","volume":"9","author":"Gurung","year":"2023","journal-title":"Int J Retin Vitr"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-grade evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.09.009_bib47","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence - indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.09.009_bib48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","article-title":"Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema","volume":"26","author":"Haritoglou","year":"2006","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.survophthal.2025.09.009_bib50","unstructured":"Higgins J., Thomas J., Chandler J., Cumpston M., Li T., Welch V. Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training; 2021. Accessed July 23, 2021. \u3008https:\/\/training.cochrane.org\/handbook\/current\u3009."},{"key":"10.1016\/j.survophthal.2025.09.009_bib51","doi-asserted-by":"crossref","unstructured":"Hsieh M.C., Cheng C.Y., Li K.H., et al. Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan. Published online 123AD. doi:10.1038\/s41598-021-04593-x.","DOI":"10.1038\/s41598-021-04593-x"},{"key":"10.1016\/j.survophthal.2025.09.009_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1108097","article-title":"A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-VEGF treatment","volume":"14","author":"Hsieh","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib53","doi-asserted-by":"crossref","unstructured":"Hu Y., Cheng Y., Xu X., et al. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with diabetic macular edema treated with ranibizumab. doi:10.1186\/s12886-019-1200-4.","DOI":"10.1186\/s12886-019-1200-4"},{"key":"10.1016\/j.survophthal.2025.09.009_bib54","doi-asserted-by":"crossref","unstructured":"Huang C.H., Yang C.H., Hsieh Y.T., Yang C.M., Ho T.C., Lai T.T. Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy. Sci Reports |. 123AD;11:5103. doi:10.1038\/s41598-021-84553-7.","DOI":"10.1038\/s41598-021-84553-7"},{"key":"10.1016\/j.survophthal.2025.09.009_bib55","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.oret.2022.03.020","article-title":"Hyperreflective dots on OCT as a predictor of treatment outcome in diabetic macular edema a systematic review","volume":"6","author":"Huang","year":"2022","journal-title":"Ophthalmol Retin"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.009_bib56","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","article-title":"The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in asian patients with diabetic macular edema","volume":"122","author":"Ishibashi","year":"2015","journal-title":"Ophthalmology"},{"issue":"1-2","key":"10.1016\/j.survophthal.2025.09.009_bib57","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1900\/RDS.2015.12.159","article-title":"Biomarkers in diabetic retinopathy","volume":"12","author":"Jenkins","year":"2015","journal-title":"Rev Diabet Stud"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcjo.2022.03.003","article-title":"Impact of retinal fluid in patients with diabetic macular edema treated with anti-VEGF in routine clinical practice","volume":"58","author":"Kalur","year":"2023","journal-title":"Can J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.009_bib59","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jcjo.2022.04.005","article-title":"OCTA changes following loading phase with intravitreal aflibercept for DME","volume":"58","author":"Kansal","year":"2023","journal-title":"Can J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.09.009_bib60","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jfo.2023.04.001","article-title":"The additive effect of intravitreal dexamethasone combined with bevacizumab in refractory diabetic macular edema","volume":"46","author":"Karimi","year":"2023","journal-title":"J Fr Ophtalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib61","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jamaophthalmol.2017.6135","article-title":"Association of changes in macular perfusion with ranibizumab treatment for diabetic macular edema: a subanalysis of the RESTORE (Extension) study","volume":"136","author":"Karst","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib62","doi-asserted-by":"crossref","unstructured":"Kessler L.J., Auffarth G.U., Bagautdinov D., Khoramnia R. Ellipsoid Zone Integrity and Visual Acuity Changes during Diabetic Macular Edema Therapy: A Longitudinal Study. Published online 2021. doi:10.1155\/2021\/8117650.","DOI":"10.1155\/2021\/8117650"},{"key":"10.1016\/j.survophthal.2025.09.009_bib63","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3390\/ph14111100","article-title":"Comparison of the 1-Year visual and anatomical outcomes between subthreshold red (670 nm) and yellow (577 nm) Micro-Pulse laser treatment for diabetic macular edema","volume":"14","author":"Kikushima","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.009_bib64","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/bjo.2008.152553","article-title":"Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulation","volume":"93","author":"Kim","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib65","doi-asserted-by":"crossref","unstructured":"Koc F., Ziya G\u00fcven Y., Egrilmez D., Ayd\u0131n E.. Optical coherence tomography biomarkers in bilateral diabetic macular edema patients with asymmetric anti-VEGF response. Published online 2021. doi:10.1080\/08820538.2021.1907423.","DOI":"10.1080\/08820538.2021.1907423"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.009_bib66","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/IAE.0b013e318176de48","article-title":"Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema","volume":"28","author":"Kook","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2025.09.009_bib67","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000481711","article-title":"Visual outcomes based on early response to Anti-Vascular endothelial growth factor treatment for diabetic macular edema ophthalmologica keywords Anti-vascular endothelial growth factor \u00b7 diabetic macular edema \u00b7 optical coherence tomography \u00b7 visual acuity","volume":"239","author":"Koyanagi","year":"2018","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2025.09.009_bib68","doi-asserted-by":"crossref","unstructured":"Kwon J.W., Kim B., Jee D., Yang &, Cho K.. Aqueous humor analyses of diabetic macular edema patients with subretinal fluid. Sci Reports |. 123AD;11:20985. doi:10.1038\/s41598-021-00442-z.","DOI":"10.1038\/s41598-021-00442-z"},{"key":"10.1016\/j.survophthal.2025.09.009_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.668107","article-title":"Age, initial central retinal thickness, and OCT biomarkers have an influence on the outcome of diabetic macular edema treated with Ranibizumab\u2013 Tri-center 12-Month Treat-and-Extend study","volume":"8","author":"Lai","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.survophthal.2025.09.009_bib70","doi-asserted-by":"crossref","unstructured":"Lai K., Huang C., Li L., et al. Anatomical and functional responses in eyes with diabetic macular edema treated with \u201c1 + PRN\u201d ranibizumab: one-year outcomes in population of mainland China. doi:10.1186\/s12886-020-01510-0.","DOI":"10.1186\/s12886-020-01510-0"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.009_bib71","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/IAE.0000000000002716","article-title":"Effect of reimbursement policy on visual outcomes in patients with diabetic macular edema treated with ranibizumab","volume":"40","author":"Lai","year":"2020","journal-title":"Retina"},{"issue":"1 Pt 1","key":"10.1016\/j.survophthal.2025.09.009_bib72","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jfma.2018.03.009","article-title":"Treatment outcomes and predicting factors for diabetic macular edema treated with ranibizumab - One-year real-life results in Taiwan","volume":"118","author":"Lai","year":"2019","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.009_bib73","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3341\/kjo.2017.0041","article-title":"Prognostic factors for functional and anatomic outcomes in patients with diabetic macular edema treated with dexamethasone implant","volume":"32","author":"Lee","year":"2018","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib74","unstructured":"Li X.Q., Meng X.X., Wang F.L., Fu Y.D. Conbercept in treating diabetic macular edema based on optical coherence tomography patterns. Biomed Res. 28(21). Accessed May 22, 2024. \u3008https:\/\/www.alliedacademies.org\/articles\/conbercept-in-treating-diabetic-macular-edema-based-on-optical-coherence-tomography-patterns-9276.html\u3009."},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.009_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-019-1168-0","article-title":"Hyperreflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with conbercept in China","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib76","article-title":"DIAbetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): a randomized double-masked non-inferiority clinical trial","author":"Lois","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.09.009_bib77","article-title":"Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema","volume":"12","author":"Markan","year":"2020","journal-title":"Ther Adv Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib78","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/IAE.0000000000003361","article-title":"Spectral domain optical coherence tomography biomarkers of retinal hyperpermeability and choroidal inflammation as predictors of short-term functional and anatomical outcomes in eyes with diabetic macular edema treated with intravitreal bevacizumab","volume":"42","author":"Mazloumi","year":"2022","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.009_bib79","first-page":"3854","article-title":"Baseline outer retinal layer thickness is associated with response of diabetic macular edema to Anti-VEGF therapy","volume":"63","author":"Mitzner","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.009_bib80","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1442-9071.2009.02104.x","article-title":"Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone","volume":"37","author":"Mohamed","year":"2009","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.009_bib81","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.oret.2017.07.003","article-title":"Correlation between deep capillary plexus perfusion and Long-Term photoreceptor recovery after diabetic macular edema treatment","volume":"2","author":"Moon","year":"2018","journal-title":"Ophthalmol Retin"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.009_bib82","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/IAE.0000000000003029","article-title":"Changes in subfoveal choroidal thickness after intravitreal dexamethasone implant therapy for diabetic macular edema","volume":"41","author":"Moon","year":"2021","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.009_bib83","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1097\/IAE.0000000000001459","article-title":"Integrity of outer retinal layers after resolution of central involved diabetic macular edema","volume":"37","author":"Muftuoglu","year":"2017","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.009_bib84","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1097\/IAE.0000000000001459","article-title":"Integrity of outer retinal layers after resolution of central involved diabetic macular edema","volume":"37","author":"Muftuoglu","year":"2017","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.009_bib85","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/ebmed-2017-110668","article-title":"Rating the certainty in evidence in the absence of a single estimate of effect","volume":"22","author":"Murad","year":"2017","journal-title":"Evid Based Med"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.009_bib86","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s10384-018-0575-8","article-title":"Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema","volume":"62","author":"Murakami","year":"2018","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.009_bib87","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1120672120925788","article-title":"Short-term outcomes of intravitreal dexamethasone in relation to biomarkers in diabetic macular edema","volume":"31","author":"Narnaware","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.009_bib88","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/ceo.12557","article-title":"Diagnostic accuracy of disorganization of the retinal inner layers in detecting macular capillary non-perfusion in diabetic retinopathy","volume":"43","author":"Nicholson","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib89","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.009_bib90","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1076\/soph.18.2.74.15854","article-title":"Role of OCT in the diagnosis and follow up of diabetic macular edema","volume":"18","author":"Panozzo","year":"2003","journal-title":"Semin Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.009_bib91","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1167\/iovs.09-4493","article-title":"Optical coherence tomography May be used to predict visual acuity in patients with macular edema","volume":"52","author":"Pelosini","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.09.009_bib92","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1159\/000515306","volume":"64","author":"Pessoa","year":"2021","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.survophthal.2025.09.009_bib93","doi-asserted-by":"crossref","unstructured":"Pessoa B., Marques J.H., Leite J., et al. Choroidal blood flow after intravitreal ranibizumab in vitrectomized and non-vitrectomized eyes with diabetic macular edema. Published online 2021. doi:10.2147\/OPTH.S325037.","DOI":"10.2147\/OPTH.S325037"},{"issue":"12","key":"10.1016\/j.survophthal.2025.09.009_bib94","first-page":"2084","article-title":"Grading OCT characteristics did not clearly predict treatment outcomes in the RELIGHT study participants","volume":"57","author":"Peto","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.009_bib95","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaophthalmol.2015.0972","article-title":"Association of disorganization of retinal inner layers with vision after resolution of Center-Involved diabetic macular edema","volume":"133","author":"Radwan","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.009_bib96","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2014.09.033","article-title":"Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema","volume":"159","author":"Rayess","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"15","key":"10.1016\/j.survophthal.2025.09.009_bib97","first-page":"2376","article-title":"Relevance of inner versus outer retinal thickness in diabetic macular edema in the RELATION study","volume":"54","author":"Ristau","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.009_bib98","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/ijo.IJO_459_20","article-title":"One-year outcomes of aflibercept for refractory diabetic macular edema in bevacizumab nonresponders","volume":"69","author":"Salimi","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib99","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.009_bib100","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/IAE.0000000000001687","article-title":"Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema","volume":"38","author":"Santos","year":"2018","journal-title":"Retina"},{"issue":"16","key":"10.1016\/j.survophthal.2025.09.009_bib101","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006459","article-title":"Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice","volume":"96","author":"Sato","year":"2017","journal-title":"Medicine"},{"issue":"32","key":"10.1016\/j.survophthal.2025.09.009_bib102","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"issue":"10","key":"10.1016\/j.survophthal.2025.09.009_bib103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206482","article-title":"Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema","volume":"13","author":"Schreur","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.survophthal.2025.09.009_bib104","unstructured":"Sch\u00fcnemann H., Brozek J., Guyatt G., Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations; 2013. Accessed August 3, 2021. \u3008https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html\u3009."},{"key":"10.1016\/j.survophthal.2025.09.009_bib105","first-page":"220","article-title":"One-Year results of using a Treat-and-Extend regimen without a loading phase with Anti-VEGF agents in patients with Treatment-Naive diabetic macular edema ophthalmologica","volume":"241","author":"Schwarzer","year":"2019","journal-title":"Res Artic Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib106","doi-asserted-by":"crossref","unstructured":"Seong Hwang H., Byung Chae J., Young Kim J., Yoon Kim D. Association Between Hyperreflective Dots on Spectral-Domain Optical Coherence Tomography in Macular Edema and Response to Treatment. Published online 2017. doi:10.1167\/iovs.17-22725.","DOI":"10.1167\/iovs.17-22725"},{"key":"10.1016\/j.survophthal.2025.09.009_bib107","unstructured":"Signorell A. Tools for Descriptive Statistics [R package DescTools version 0.99.54]. Published online February 3, 2024. Accessed June 9, 2024. \u3008https:\/\/cran.r-project.org\/package=DescTools\u3009."},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib108","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s12325-016-0310-0","article-title":"Using Patient-Level data to develop meaningful Cross-Trial comparisons of visual impairment in individuals with diabetic macular edema","volume":"33","author":"Sivaprasad","year":"2016","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.009_bib109","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1600-0420.2007.01048.x","article-title":"The predictive value of optical coherence tomography after grid laser photocoagulation for diffuse diabetic macular oedema","volume":"86","author":"Soliman","year":"2008","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.009_bib110","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ophtha.2015.02.036","article-title":"Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab","volume":"122","author":"Sophie","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.009_bib111","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.survophthal.2022.11.008","article-title":"Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods","volume":"68","author":"Sorour","year":"2023","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.009_bib112","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with Center-Involved diabetic macular edema","volume":"132","author":"Sun","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.009_bib113","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with Center-Involved diabetic macular edema","volume":"132","author":"Sun","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.009_bib114","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/bjophthalmol-2021-319587","article-title":"OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study","volume":"107","author":"Szeto","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib115","doi-asserted-by":"crossref","unstructured":"Terada N., Murakami T., Uji A., Dodo Y., Mori Y., Tsujikawa A. Hyperreflective Walls in Foveal Cystoid Spaces as a Biomarker of Diabetic Macular Edema Refractory to Anti-VEGF Treatment. doi:10.1038\/s41598-020-64332-6.","DOI":"10.1038\/s41598-020-64332-6"},{"key":"10.1016\/j.survophthal.2025.09.009_bib116","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s10792-023-02674-6","article-title":"Morphological changes of foveal cysts as a predictor for visual response to anti-vascular endothelial growth factor treatments in diabetic macular edema degenerative cyst in DME","volume":"43","author":"Tsai","year":"2023","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib117","first-page":"105","article-title":"Patterns of ellipsoid zone change associated with visual outcome for diabetic macular oedema","author":"Tsai","year":"2022","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.survophthal.2025.09.009_bib118","doi-asserted-by":"crossref","DOI":"10.1080\/08820538.2021.1889620","article-title":"Wu Ho-Su memorial hospital K. Intravitreal aflibercept versus ranibizumab for diabetic macular edema in a Taiwanese health service setting","volume":"36","author":"Tsai","year":"2021","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.009_bib119","doi-asserted-by":"crossref","unstructured":"Uzel M.M., Karahan E., Koroglu Canli M., Guler C. The prognostic role of optical coherence tomography in diabetic macular edema patients undergoing early dexamethasone implant shift. \u3008https:\/\/doi-org.myaccess.library.utoronto.ca\/101177\/11206721211019569\u3009. 2021;32(3):1562-1569. doi:10.1177\/11206721211019569.","DOI":"10.1177\/11206721211019569"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.009_bib120","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/eye.2011.84","article-title":"Qualitative and quantitative OCT response of diffuse diabetic macular oedema to macular laser photocoagulation","volume":"25","author":"Vemala","year":"2011","journal-title":"Eye"},{"issue":"9","key":"10.1016\/j.survophthal.2025.09.009_bib121","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00417-021-05083-6","article-title":"Intracystic hyperreflective material in centre-involving diabetic macular oedema","volume":"259","author":"Venkatesh","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.009_bib122","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/aos.13294","article-title":"Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema","volume":"95","author":"Vujosevic","year":"2017","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.009_bib123","first-page":"430","article-title":"Assessment of inflammation biomarkers in diabetic macular edema treated with intravitreal dexamethasone implant","volume":"37","author":"Vural","year":"2021"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.009_bib124","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/s41433-021-01672-1","article-title":"Fluctuations in macular thickness in patients with diabetic macular oedema treated with anti-vascular endothelial growth factor agents","volume":"36","author":"Wang","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2025.09.009_bib125","unstructured":"What is GRADE? | BMJ Best Practice. Accessed July 21, 2024. https:\/\/bestpractice.bmj.com\/info\/us\/toolkit\/learn-ebm\/what-is-grade\/#."},{"key":"10.1016\/j.survophthal.2025.09.009_bib126","doi-asserted-by":"crossref","unstructured":"Willmann G., Brunno Nepomuceno A., Messias K., et al. Clinical Research\u00b7 Foveal thickness reduction after anti-vascular endothelial growth factor treatment in chronic diabetic macular edema. doi:10.18240\/ijo.2017.05.17.","DOI":"10.18240\/ijo.2017.05.17"},{"key":"10.1016\/j.survophthal.2025.09.009_bib127","doi-asserted-by":"crossref","unstructured":"Wu P.C., Lai C.H., Chen C.L., Kuo C.N. Optical Coherence Tomographic Patterns in Diabetic Macula Edema Can Predict the Effects of Intravitreal Bevacizumab Injection as Primary Treatment. \u3008https:\/\/home.liebertpub.com\/jop\u3009. 2012;28(1):59-64. doi:10.1089\/JOP.2011.0070.","DOI":"10.1089\/jop.2011.0070"},{"key":"10.1016\/j.survophthal.2025.09.009_bib128","doi-asserted-by":"crossref","unstructured":"Yoshitake T., Murakami T., Suzuma K., Dodo Y., Fujimoto M., Tsujikawa A. Hyperreflective Foci in the Outer Retinal Layers as a Predictor of the Functional Efficacy of Ranibizumab for Diabetic Macular Edema. Published online 2020. doi:10.1038\/s41598-020-57646-y.","DOI":"10.1038\/s41598-020-57646-y"},{"key":"10.1016\/j.survophthal.2025.09.009_bib129","doi-asserted-by":"crossref","unstructured":"Yoshitake T., Murakami T., Yoshitake S., et al. Anti-Fumarase Antibody as a Predictor of Functional Efficacy of Anti-VEGF Therapy for Diabetic Macular Edema. Published online 2019. doi:10.1167\/iovs.18-26209.","DOI":"10.1167\/iovs.18-26209"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.009_bib130","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-023-02973-7","article-title":"Predictive effect of TCED-HFV grading and imaging biomarkers on anti-VEGF therapy in diabetic macular edema","volume":"23","author":"Yu","year":"2023","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.09.009_bib131","first-page":"1501","article-title":"\u57fa\u4e8e\u5149\u5b66\u76f8\u5e72\u65ad\u5c42\u626b\u63cf\u7684\u4e0d\u540c\u7c7b\u578b\u7cd6\u5c3f\u75c5\u6027\u9ec4\u6591\u6c34\u80bf\u5bf9\u5eb7\u67cf\u897f\u666e\u7684\u6cbb\u7597\u53cd\u5e94","volume":"41","author":"Zhang","year":"2021","journal-title":"J South Med Univ"},{"key":"10.1016\/j.survophthal.2025.09.009_bib132","doi-asserted-by":"crossref","unstructured":"Zur D., Iglicki M., Busch C., Invernizzi A., Mariussi M., Loewenstein A. OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. doi:10.1016\/j.ophtha.2017.08.031.","DOI":"10.1016\/j.ophtha.2017.08.031"},{"key":"10.1016\/j.survophthal.2025.09.009_bib133","doi-asserted-by":"crossref","unstructured":"Zur D., Iglicki M., Sala-Puigdollers A., et al. Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. doi:10.1111\/aos.14230.","DOI":"10.1111\/aos.14230"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725001766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725001766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T18:02:20Z","timestamp":1768845740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625725001766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":133,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0039625725001766"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.09.009","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}